TY - GEN
T1 - Group 1 ITI Consensus Report
T2 - ITI Consensus Conference
AU - Jung, Ronald E
AU - Al-Nawas, Bilal
AU - Araujo, Mauricio
AU - Avila-Ortiz, Gustavo
AU - Barter, Stephen
AU - Brodala, Nadine
AU - Chappuis, Vivianne
AU - Chen, Bo
AU - De Souza, Andre
AU - Almeida, Ricardo Faria
AU - Fickl, Stefan
AU - Finelle, Gary
AU - Ganeles, Jeffrey
AU - Gholami, Hadi
AU - Hammerle, Christoph
AU - Jensen, Simon
AU - Jokstad, Asbjørn
AU - Katsuyama, Hideaki
AU - Kleinheinz, Johannes
AU - Kunavisarut, Chatchai
AU - Mardas, Nikos
AU - Monje, Alberto
AU - Papaspyridakos, Panos
AU - Payer, Michael
AU - Schiegnitz, Eik
AU - Smeets, Ralf
AU - Stefanini, Martina
AU - Ten Bruggenkate, Christiaan
AU - Vazouras, Konstantinos
AU - Weber, Hans-Peter
AU - Weingart, Dieter
AU - Windisch, Péter
N1 - Conference code: 6
PY - 2018/10
Y1 - 2018/10
N2 - Objectives: The aim of Working Group 1 was to address the influence of different local (implant length, diameter, and design) and systemic (medications) factors on clinical, radiographic, and patient-reported outcomes in implant dentistry. Focused questions on (a) short posterior dental implants (≤6 mm), (b) narrow diameter implants, (c) implant design (tapered compared to a non-tapered implant design), and (d) medication-related dental implant failures were addressed. Materials and methods: Four systematic reviews were prepared in advance of the Consensus Conference and were discussed among the participants of Group 1. Consensus statements, clinical recommendations, and recommendations for future research were based on structured group discussions until consensus was reached among the entire expert Group 1. The statements were then presented and accepted following further discussion and modifications as required by the plenary. Results: Short implants (≤6 mm) revealed a survival rate ranging from 86.7% to 100%, whereas standard implant survival rate ranged from 95% to 100% with a follow-up from 1 to 5 years. Short implants demonstrated a higher variability and a higher Risk Ratio [RR: 1.24 (95% CI: 0.63, 2.44, p = 0.54)] for failure compared to standard implants. Narrow diameter implants (NDI) have been classified into three categories: Category 1: Implants with a diameter of <2.5 mm (“Mini-implants”); Category 2: Implants with a diameter of 2.5 mm to <3.3 mm; Category 3: Implants with a diameter of 3.3 mm to 3.5 mm. Mean survival rates were 94.7 ± 5%, 97.3 ± 5% and 97.7 ± 2.3% for category 1, 2 and 3. Tapered versus non-tapered implants demonstrated only insignificant differences regarding clinical, radiographic, and patient-reported outcomes. The intake of certain selective serotonin reuptake inhibitors and proton pump inhibitors is associated with a statistically significant increased implant failure rate. The intake of bisphosphonates related to the treatment of osteoporosis was not associated with an increased implant failure rate. Conclusions: It is concluded that short implants (≤6 mm) are a valid option in situations of reduced bone height to avoid possible morbidity associated with augmentation procedures; however, they reveal a higher variability and lower predictability in survival rates. Narrow diameter implants with diameters of 2.5 mm and more demonstrated no difference in implant survival rates compared to standard diameter implants. In contrast, it is concluded that narrow diameter implants with diameters of less than 2.5 mm exhibited lower survival rates compared to standard diameter implants. It is further concluded that there are no differences between tapered versus non-tapered dental implants. Certain medications such as selective serotonin reuptake inhibitors and proton pump inhibitors showed an association with a higher implant failure rate.
AB - Objectives: The aim of Working Group 1 was to address the influence of different local (implant length, diameter, and design) and systemic (medications) factors on clinical, radiographic, and patient-reported outcomes in implant dentistry. Focused questions on (a) short posterior dental implants (≤6 mm), (b) narrow diameter implants, (c) implant design (tapered compared to a non-tapered implant design), and (d) medication-related dental implant failures were addressed. Materials and methods: Four systematic reviews were prepared in advance of the Consensus Conference and were discussed among the participants of Group 1. Consensus statements, clinical recommendations, and recommendations for future research were based on structured group discussions until consensus was reached among the entire expert Group 1. The statements were then presented and accepted following further discussion and modifications as required by the plenary. Results: Short implants (≤6 mm) revealed a survival rate ranging from 86.7% to 100%, whereas standard implant survival rate ranged from 95% to 100% with a follow-up from 1 to 5 years. Short implants demonstrated a higher variability and a higher Risk Ratio [RR: 1.24 (95% CI: 0.63, 2.44, p = 0.54)] for failure compared to standard implants. Narrow diameter implants (NDI) have been classified into three categories: Category 1: Implants with a diameter of <2.5 mm (“Mini-implants”); Category 2: Implants with a diameter of 2.5 mm to <3.3 mm; Category 3: Implants with a diameter of 3.3 mm to 3.5 mm. Mean survival rates were 94.7 ± 5%, 97.3 ± 5% and 97.7 ± 2.3% for category 1, 2 and 3. Tapered versus non-tapered implants demonstrated only insignificant differences regarding clinical, radiographic, and patient-reported outcomes. The intake of certain selective serotonin reuptake inhibitors and proton pump inhibitors is associated with a statistically significant increased implant failure rate. The intake of bisphosphonates related to the treatment of osteoporosis was not associated with an increased implant failure rate. Conclusions: It is concluded that short implants (≤6 mm) are a valid option in situations of reduced bone height to avoid possible morbidity associated with augmentation procedures; however, they reveal a higher variability and lower predictability in survival rates. Narrow diameter implants with diameters of 2.5 mm and more demonstrated no difference in implant survival rates compared to standard diameter implants. In contrast, it is concluded that narrow diameter implants with diameters of less than 2.5 mm exhibited lower survival rates compared to standard diameter implants. It is further concluded that there are no differences between tapered versus non-tapered dental implants. Certain medications such as selective serotonin reuptake inhibitors and proton pump inhibitors showed an association with a higher implant failure rate.
KW - Consensus
KW - Dental Implantation, Endosseous
KW - Dental Implants
KW - Dental Prosthesis Design
KW - Dental Restoration Failure
KW - Diphosphonates/adverse effects
KW - Humans
KW - Jaw, Edentulous, Partially/rehabilitation
KW - Osteoporosis/complications
KW - Patient Reported Outcome Measures
KW - Proton Pump Inhibitors/adverse effects
KW - Radiography, Dental
KW - Serotonin Uptake Inhibitors/adverse effects
KW - Survival Analysis
KW - Systematic Reviews as Topic
U2 - 10.1111/clr.13342
DO - 10.1111/clr.13342
M3 - Conference article
C2 - 30328189
SN - 0905-7161
VL - 29
SP - 69
EP - 77
JO - Clinical Oral Implants Research
JF - Clinical Oral Implants Research
IS - S16
Y2 - 17 April 2018 through 19 April 2018
ER -